The notices it replaced
- Reissues: PAR-23-279 Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $693,075 in first-year total cost, median $693,075.
Most frequent study sections
- Cancer Prevention Study Section[CPSS]1
Most frequent institutions
- YALE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Targeting pancreatic endocrine-exocrine signaling in cancer development with incretin mimetics1R01CA296916-01 · under PAR-23-279 | MUZUMDAR, MANDAR DEEPAK | YALE UNIVERSITY, CT | $693,075 | CPSS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.